Trial Profile
Phase 3, multicenter, multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with acute peripheral arterial occlusion (NAPA-3)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Alfimeprase (Primary)
- Indications Embolism and thrombosis; Peripheral arterial occlusive disorders
- Focus Registrational; Therapeutic Use
- Acronyms NAPA-3
- Sponsors Nuvelo
- 02 Aug 2022 This trial has been completed in Netherland and Hungary (End Date: 26 Jun 2007), according to European Clinical Trials Database record.
- 01 Mar 2010 Primary endpoint results published in the Journal of Vascular Surgery
- 14 Jan 2008 Status changed from in progress to discontinued.